Literature DB >> 8958335

Phenotypic differences in Angelman syndrome patients: imprinting mutations show less frequently microcephaly and hypopigmentation than deletions.

J Bürger1, J Kunze, K Sperling, A Reis.   

Abstract

Angelman syndrome (AS) is a relatively frequent disorder of psychomotor development caused by loss of function of a gene from chromosome 15q11-q13, a region subject to genomic imprinting. The AS gene(s) is exclusively expressed from the maternal chromosome. Several kinds of mutations have been found to cause AS. More than half of the cases exhibit a deletion of the maternal 15q11-q13 region. Recently, we and others described a new mutation type, the imprinting mutation, characterised by normal, biparental inheritance but aberrant methylation patterns of the entire chromosomal region. In AS, a paternal imprint is found on the maternal chromosome probably leading to functional inactivation of the AS gene(s). We have now compared the phenotype of 9 AS patients with imprinting mutation to that of nine age-matched ones with a maternally derived deletion. Both groups were evaluated for 19 common AS symptoms. All patients, independently of their molecular findings, showed classical AS symptoms such s mental retardation, delayed motor development, and absent speech. In contrast, for two signs, hypopigmentation and microcephaly, a different distribution among both groups was observed. Only one of nine AS patients with an imprinting mutation, but seven of nine in the deletion control group showed either symptom. Our results suggest that imprinting mutations, in contrast to deletions, cause only incomplete loss of gene function or that maternally derived deletions affect also genes not subject to genomic imprinting. We conclude that AS is caused by loss of function of a major gene that is imprinted but that there are also other genes that contribute to the phenotype when in hemizygous condition.

Entities:  

Mesh:

Year:  1996        PMID: 8958335     DOI: 10.1002/(SICI)1096-8628(19961211)66:2<221::AID-AJMG19>3.0.CO;2-V

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  8 in total

1.  Angelman syndrome: Mutations influence features in early childhood.

Authors:  Wen-Hann Tan; Carlos A Bacino; Steven A Skinner; Irina Anselm; Rene Barbieri-Welge; Astrid Bauer-Carlin; Arthur L Beaudet; Terry Jo Bichell; Jennifer K Gentile; Daniel G Glaze; Lucia T Horowitz; Sanjeev V Kothare; Hye-Seung Lee; Mark P Nespeca; Sarika U Peters; Trilochan Sahoo; Dean Sarco; Susan E Waisbren; Lynne M Bird
Journal:  Am J Med Genet A       Date:  2011-01       Impact factor: 2.802

2.  Distinct phenotypes distinguish the molecular classes of Angelman syndrome.

Authors:  A C Lossie; M M Whitney; D Amidon; H J Dong; P Chen; D Theriaque; A Hutson; R D Nicholls; R T Zori; C A Williams; D J Driscoll
Journal:  J Med Genet       Date:  2001-12       Impact factor: 6.318

3.  Different mechanisms and recurrence risks of imprinting defects in Angelman syndrome.

Authors:  J Bürger; K Buiting; B Dittrich; S Gross; C Lich; K Sperling; B Horsthemke; A Reis
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

Review 4.  The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13.

Authors:  Amber Hogart; David Wu; Janine M LaSalle; N Carolyn Schanen
Journal:  Neurobiol Dis       Date:  2008-09-18       Impact factor: 5.996

Review 5.  Angelman syndrome: a review of the clinical and genetic aspects.

Authors:  J Clayton-Smith; L Laan
Journal:  J Med Genet       Date:  2003-02       Impact factor: 6.318

Review 6.  Angelman syndrome: review of clinical and molecular aspects.

Authors:  Lynne M Bird
Journal:  Appl Clin Genet       Date:  2014-05-16

7.  A novel UBE3A sequence variant identified in eight related individuals with neurodevelopmental delay, results in a phenotype which does not match the clinical criteria of Angelman syndrome.

Authors:  Amber Geerts-Haages; Stijn N V Bossuyt; Inge den Besten; Hennie Bruggenwirth; Ineke van der Burgt; Helger G Yntema; A Mattijs Punt; Alice Brooks; Ype Elgersma; Ben Distel; Marlies Valstar
Journal:  Mol Genet Genomic Med       Date:  2020-09-05       Impact factor: 2.183

8.  Behavior and neuropsychiatric manifestations in Angelman syndrome.

Authors:  Karine Pelc; Guy Cheron; Bernard Dan
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.